ARCC-4 是一种基于 PROTAC 技术的纳摩尔雄激素受体 (AR) 降解剂，D50 值为 5 nM。ARCC-4 是一种基于恩杂鲁胺的 von Hippel-Lindau (VHL) 招募的 AR PROTAC，能够有效降解与抗雄激素研究相关的 AR 突变体。

ARD-69 is a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. ARD-69 induces degradation of AR protein in AR-positive prostate cancer cell lines in a dose- and time-dependent manner. ARD-69 achieves DC50 values of 0.86, 0.76, and 10.4 nM in LNCaP, VCaP, and 22Rv1 AR+ prostate cancer cell lines, respectively. ARD-69 is capable of reducing the AR protein level by >95% in these prostate cancer cell lines and effectively suppressing AR-regulated gene expression.